Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) – Pipeline Review, H1 2017’, provides in depth analysis on Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47). Additionally, the report provides an overview of key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease and Metabolic Disorders under development targeting Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects

The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

Surface Oncology Inc

Trillium Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

Surface Oncology Inc

Trillium Therapeutics Inc

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles

ALX-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-6H12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hu-5F9G4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CD47 for Immuno-Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PSTx-23 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD47 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRF-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tigecycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-622 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Dormant Products

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Product Development Milestones

Featured News & Press Releases

Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade

May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients

Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

Mar 31, 2017: Aurigene to Present Data on CD47-SIRPÃŽ interaction program at the AACR 2017

Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-621

Feb 02, 2017: Trillium Therapeutics Provides Update On TTI-622

Jan 31, 2017: Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial

Dec 15, 2016: Surface Oncology Appoints Robert Ross, MD as Chief Medical Officer

Dec 03, 2016: Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

Dec 02, 2016: Surface Oncology CD47 Program Demonstrates Promising Anti-Tumor Activity in Hematological Disease Models

Nov 29, 2016: Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Pipeline by Celgene Corp, H1 2017

Pipeline by Forty Seven Inc, H1 2017

Pipeline by Surface Oncology Inc, H1 2017

Pipeline by Trillium Therapeutics Inc, H1 2017

Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports